» Articles » PMID: 33086677

Systems Biology and Experimental Model Systems of Cancer

Overview
Journal J Pers Med
Date 2020 Oct 22
PMID 33086677
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past decade, we have witnessed an increasing number of large-scale studies that have provided multi-omics data by high-throughput sequencing approaches. This has particularly helped with identifying key (epi)genetic alterations in cancers. Importantly, aberrations that lead to the activation of signaling networks through the disruption of normal cellular homeostasis is seen both in cancer cells and also in the neighboring tumor microenvironment. Cancer systems biology approaches have enabled the efficient integration of experimental data with computational algorithms and the implementation of actionable targeted therapies, as the exceptions, for the treatment of cancer. Comprehensive multi-omics data obtained through the sequencing of tumor samples and experimental model systems will be important in implementing novel cancer systems biology approaches and increasing their efficacy for tailoring novel personalized treatment modalities in cancer. In this review, we discuss emerging cancer systems biology approaches based on multi-omics data derived from bulk and single-cell genomics studies in addition to existing experimental model systems that play a critical role in understanding (epi)genetic heterogeneity and therapy resistance in cancer.

Citing Articles

Exploiting Matrix Stiffness to Overcome Drug Resistance.

Aydin H, Ozcelikkale A, Acar A ACS Biomater Sci Eng. 2024; 10(8):4682-4700.

PMID: 38967485 PMC: 11322920. DOI: 10.1021/acsbiomaterials.4c00445.


A war on many fronts: cross disciplinary approaches for novel cancer treatment strategies.

Del Pino Herrera A, Ferrall-Fairbanks M Front Genet. 2024; 15:1383676.

PMID: 38873108 PMC: 11169904. DOI: 10.3389/fgene.2024.1383676.


Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.

Basar O, Mohammed S, Qoronfleh M, Acar A Front Cell Dev Biol. 2024; 12:1369597.

PMID: 38813084 PMC: 11133583. DOI: 10.3389/fcell.2024.1369597.


Tumor-Microenvironment-on-Chip Platform for Assessing Drug Response in 3D Dynamic Culture.

Aydin H, Moon H, Han B, Ozcelikkale A, Acar A Methods Mol Biol. 2024; 2764:265-278.

PMID: 38393600 DOI: 10.1007/978-1-0716-3674-9_17.


Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach.

Adhikary S, Pathak S, Palani V, Acar A, Banerjee A, Al-Dewik N Biomedicines. 2024; 12(1).

PMID: 38255322 PMC: 10813720. DOI: 10.3390/biomedicines12010217.


References
1.
Samur M, Yan Z, Wang X, Cao Q, Munshi N, Li C . canEvolve: a web portal for integrative oncogenomics. PLoS One. 2013; 8(2):e56228. PMC: 3572035. DOI: 10.1371/journal.pone.0056228. View

2.
Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J . Tumour evolution inferred by single-cell sequencing. Nature. 2011; 472(7341):90-4. PMC: 4504184. DOI: 10.1038/nature09807. View

3.
Cao Q, Zhou M, Wang X, Meyer C, Zhang Y, Chen Z . CaSNP: a database for interrogating copy number alterations of cancer genome from SNP array data. Nucleic Acids Res. 2010; 39(Database issue):D968-74. PMC: 3013814. DOI: 10.1093/nar/gkq997. View

4.
Kelso T, Porter D, Amaral M, Shokhirev M, Benner C, Hargreaves D . Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife. 2017; 6. PMC: 5643100. DOI: 10.7554/eLife.30506. View

5.
Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View